Does CoQ10 Lower Blood Pressure? (What Trials Report)

Does CoQ10 Lower Blood Pressure? (What Trials Report)

The rest of this page unpacks that answer. What the mechanism is, what each major review reported, who the participants actually were, how large the reported changes were, and what is worth raising with a clinician before changing anything.

What is CoQ10, briefly?

Coenzyme Q10 is a fat soluble compound your cells make themselves and also absorb in small amounts from food. It sits in the inner membrane of mitochondria, where it carries electrons along the respiratory chain that produces ATP, and it doubles as a fat soluble antioxidant in cell membranes and on circulating lipoproteins. Levels can be measured in plasma or serum, and because the molecule travels with lipids, your cholesterol level influences the number you get back. The biomarker page linked above owns the detail on what the test measures, how levels are interpreted, and what a high or low result can reflect. This page sticks to a single question, whether taking it changes a cuff reading.

Why would a nutrient affect blood pressure at all?

Because arterial pressure depends partly on how readily the lining of your arteries relaxes, and that relaxation is sensitive both to oxidative stress and to the energy supply of vascular cells. CoQ10 sits at the intersection of the two.

The endothelium, the single cell layer lining every blood vessel, releases nitric oxide, a short lived signal that tells the surrounding smooth muscle to loosen. Nitric oxide is chemically fragile. Reactive oxygen species, superoxide in particular, react with it within moments and remove it before it can act. Less available nitric oxide means stiffer, more constricted vessels, and over years, higher readings.

CoQ10 is one of the few fat soluble antioxidants that sits inside membranes and on circulating lipoproteins, which is exactly where that chemistry happens. Research suggests that CoQ10 may support endothelial function by limiting the oxidative stress that consumes nitric oxide and by damping inflammatory signalling in the vessel wall 1. A review of CoQ10 in cardiovascular disorders of ageing reported that supplementation is associated with improvements in measures of endothelial function across several of the studies it surveyed 2.

There is a second, less discussed route. Vascular smooth muscle and the heart are energy hungry tissues, and CoQ10 is required for mitochondrial ATP production in both. Mitochondrial efficiency tends to fall with age and in cardiac disease, and the hypothesis is that supporting the electron carrier supports the contraction and relaxation work those tissues do.

A plausible mechanism is not an effect. Many compounds improve a laboratory measure of vascular function without moving a cuff reading in a living person, and the gap between a mechanism and a millimetre of mercury is where most supplement claims come apart. The only way to answer the question is to look at what was actually measured in people.

What do the pooled analyses actually report?

They report measurable reductions in some analyses and no clinically meaningful effect in the most recent and most conservative one, all drawn from a thin base of small, short trials 5 3. That disagreement is the single most important fact about this topic.

Source Who was studied What it reported
Cochrane review, 2016 update 3 Adults with primary hypertension, a very small number of randomised trials Concluded the available evidence did not show a clinically significant effect of CoQ10 on blood pressure
Cochrane review, 2009 version 4 Adults with primary hypertension Pooled reductions in systolic and diastolic pressure, while cautioning that the included studies might be unreliable and the question unresolved
Meta-analysis of clinical trials, 2007 5 Twelve clinical trials in people with hypertension Reported that CoQ10 has the potential to lower systolic pressure by up to 17 mmHg and diastolic pressure by up to 10 mmHg without significant side effects
Systematic review, 2022 6 People with cardiovascular disease and hypertension Described CoQ10 as a possible adjunct alongside standard care, with inconsistent results and a need for larger trials
Controlled trial, 2002 7 Adults with type 2 diabetes Reported improvements in blood pressure and in glycaemic control over the study period
Randomised placebo controlled trial, 2001 8 Adults with isolated systolic hypertension Reported a greater fall in systolic pressure with CoQ10 than with placebo

Read the table as a spread of findings rather than a verdict. The earlier pooled work is the source of almost every confident headline you will see, and the later Cochrane update is the reason cautious clinicians stay unconvinced. A systematic review of trials in older adults with cardiovascular disease or hypertension found the effects on hypertension inconclusive 6.

Why do reviews of the same trials reach different conclusions?

Because reviews make different choices about what to include, how to weight quality, and how to handle the risk that small size and imperfect blinding inflate a reported result.

With so few to go on, a single inclusion decision can change the overall answer. Drop one result with an unusually large effect, or downgrade it for unclear randomisation, and an apparently convincing reduction shrinks toward zero. The 2009 Cochrane version pooled the small set of eligible trials and reported falls in both systolic and diastolic pressure, while flagging that the included studies might not be reliable 4. The 2016 update, working from a similar evidence base with a stricter reading of study quality, concluded that the evidence did not demonstrate a clinically significant effect 3.

That is not two groups contradicting each other on facts. It is two readings of the same thin dataset, one asking what the numbers add up to and the other asking how much those numbers can be trusted. A broader 2022 systematic review landed in between, describing CoQ10 as a plausible adjunct whose effect size remains unsettled 6.

For a reader, the practical translation is simple. When the strongest reviews disagree, the effect is almost certainly not large or consistent, because a large consistent effect survives methodological disagreement. Nobody argues about whether reducing body weight or sodium intake moves blood pressure.

Who took part in these trials, and does that include you?

Mostly adults who already had elevated blood pressure or an established cardiovascular or metabolic condition, studied in small groups over weeks to months rather than years.

That matters for three reasons. First, a compound tends to show its biggest apparent effect in people furthest from normal, so results from people with established hypertension do not transfer cleanly to someone with borderline readings. Second, several of the trials recruited specific populations rather than the general public 7 8. One controlled trial enrolled adults with type 2 diabetes and reported improvements in both blood pressure and glycaemic control 7. Another randomised placebo controlled trial recruited people with isolated systolic hypertension, a pattern more common with age and arterial stiffening, and reported a greater systolic fall with CoQ10 than placebo 8.

Third, almost everyone in these trials continued their usual care 6. These were studies of something added on top of existing management, not studies of a replacement for it 6. Nothing in this area supports swapping prescribed blood pressure medicine for a supplement, and that framing never appears in the papers themselves.

So the honest reading is narrow. What is known applies most to older adults with existing hypertension or metabolic disease who are already under clinical care, and says very little about a healthy 35 year old with readings in the normal range who wants a nudge lower.

How much weight should the largest reported reductions carry?

Treat them as an upper bound from favourable conditions, not an expected result. The 2007 meta-analysis phrased its finding as a potential, reporting that CoQ10 has the potential to lower systolic pressure by up to 17 mmHg and diastolic pressure by up to 10 mmHg 5. The word potential is doing real work in that sentence, and later reviews did not confirm effects of that magnitude 3.

There are predictable reasons an early pooled figure runs high. Small numbers of participants produce noisy results, and noisy results that happen to be positive are more likely to be published and more likely to be cited. When blinding is incomplete, it invites a placebo response, which is unusually strong for blood pressure because measurement itself is behavioural. Short follow up periods catch the early part of a response curve that may flatten. And the formulations differed between products, since absorption of ubiquinone and ubiquinol preparations varies considerably, which widens the scatter in any pooled estimate.

A fair summary is that any real effect is likely to sit at the modest end, variable between individuals, and smaller than the effect of the things that reliably move blood pressure. Sodium intake, body composition, alcohol, sleep quality, untreated sleep apnoea and regular aerobic activity all have a stronger and better replicated relationship with cuff readings than any single supplement does.

Does your own blood level change the picture?

A blood level tells you where you sit, not whether supplementing will move your blood pressure, because it is not established that baseline level predicts the response.

Measure Typical lab reference range FitScript optimal range
Coenzyme Q10, plasma or serum, µg/mL 0.5 to 2.5 1 to 2

Reference ranges are typical lab reference ranges and vary by laboratory, assay, age and sex, so read your own report against its own range. The optimal range shown is FitScript's optimization target, not a diagnostic cut-off, and no single value defines a condition.

Use the result the way a clinician would. The observation is a number inside or outside a range. The meaning is hedged, since a lower value may reflect reduced synthesis with age, low circulating lipids, certain medicines, or simply assay variation between labs, and a higher value usually reflects recent supplement intake or higher cholesterol carrying the molecule. The next step is a conversation, not a purchase. A level toward the lower end of the standard range, alongside persistently elevated blood pressure, is worth discussing with a clinician who can see the rest of your picture.

What a level will not do is forecast a blood pressure response. That link has not been established in the published trials, and anyone implying otherwise is extrapolating well past the data.

What is the cholesterol-medicine connection people keep raising?

Some cholesterol-lowering medicines reduce circulating CoQ10, which is why the two topics are so often discussed together. The enzyme those medicines inhibit sits upstream of both cholesterol synthesis and CoQ10 synthesis, and because CoQ10 travels on lipoproteins, a fall in LDL mechanically lowers the measured blood level as well.

That is context, not instruction. A 2010 clinical review examined CoQ10 both for hypertension and for statin associated muscle symptoms and reported that the evidence was not strong enough to support routine use for either purpose 11.

Nothing on this page is a reason to start, stop or alter any prescribed medicine. Lipid lowering therapy is prescribed for reasons that have nothing to do with a supplement decision, and a licensed provider evaluates whether any change is appropriate. If a lower CoQ10 result appears on a panel while you are on lipid therapy, the useful move is to bring the result to the prescriber who ordered the therapy rather than to act on it independently.

What does the evidence look like in heart failure and angina?

The heart failure case is more developed than the blood pressure one, though still debated, and it is often what people are half remembering when they say CoQ10 is good for the heart.

Research suggests that, in heart failure, CoQ10 has been studied as an adjunct to standard care with reported effects on functional measures, while individual trials have varied in size and design 9. A systematic review spanning physical exercise, hypertension and heart failure reported possible benefits across these settings while noting that methodological limitations made firm conclusions difficult 10. A later review of cardiovascular disorders of ageing covered heart failure, hypertension and endothelial dysfunction together, arguing that the mitochondrial and antioxidant rationale is consistent across all three 2.

Two cautions follow. First, what holds in heart failure does not transfer to blood pressure in otherwise well people, since the failing heart is a different physiological problem with different limiting factors. Second, every one of these studies describes an addition to clinical care delivered under supervision, in people whose condition was being actively managed 6. None of it describes self directed use in place of medical care, and nobody with a cardiac diagnosis should add a supplement without telling the cardiology team looking after them.

What makes this evidence base weaker than it looks?

The volume of citations is larger than the volume of reliable data, which is a common pattern for well studied supplements.

Four weaknesses recur. Sample sizes are small, and the trials eligible for the strictest reviews have involved modest numbers of participants, which leaves pooled estimates wide and unstable 3. Durations are short, typically running weeks to a few months, so nothing in this literature speaks to effects over years, which is the timescale that matters for cardiovascular risk. Formulations and absorption differ between products, and because CoQ10 is poorly and variably absorbed, two products can deliver quite different internal exposure. And blinding has often been hard to verify, which matters because blood pressure responds to expectation and to the measurement setting itself.

Add to that publication bias, which can make the overall picture read more enthusiastic than it is. The 2022 systematic review reflected exactly that tension, describing CoQ10 as a plausible adjunct while calling for larger and better designed trials 6.

None of this makes CoQ10 useless. It makes the honest answer provisional, and it means the compound should be judged alongside the interventions that are well established rather than instead of them.

Which markers are worth looking at alongside it?

Blood pressure is an output of several systems, so a single nutrient marker rarely explains it. The panel that gives context is broader.

Lipids, including ApoB and a full cholesterol profile, matter here twice over, since they carry CoQ10 in blood and they sit alongside blood pressure in cardiovascular risk. Fasting glucose, fasting insulin and HbA1c describe metabolic status. Kidney markers such as creatinine, eGFR and urine albumin are central, because the kidney both influences blood pressure and is affected by it. Electrolytes, particularly sodium and potassium, reflect intake and regulatory signalling. High sensitivity CRP gives a read on inflammatory load, which connects to the endothelial mechanisms described above. Thyroid function, vitamin D, homocysteine and vitamin B12 round out the picture, and B12 in particular comes up often in blood pressure questions.

This is the case for testing broadly rather than chasing one marker. FitScript members have 150+ biomarkers tested per year, and Atlas, FitScript's AI health advisor, reads those results together rather than one line at a time, which is the only way a pattern across lipids, metabolic markers and kidney function becomes visible.

What should nobody do on the strength of a supplement trial?

Change or stop prescribed blood pressure medicine. That is the one firm line in this entire topic, and it is firm regardless of how promising a supplement looks.

Blood pressure medicines are adjusted by the clinician who prescribed them, using readings over time and the rest of your clinical picture. A supplement with a modest, contested effect does not substitute for that, and stopping therapy to test a theory exposes you to risk that nobody has measured. If you want to try CoQ10, the appropriate route is to tell your prescriber and your pharmacist first, so it is recorded alongside everything else you take and any interaction is considered in advance.

Two more things worth avoiding. Do not treat a single home reading as a trend, because blood pressure swings through the day and a one off number says little. And do not ignore a result that sits outside the range on a report, including a result you dislike. A reading that is persistently elevated, or a lab value flagged outside the standard range, is worth discussing with a clinician rather than filed away.

This page is educational and is not medical advice.

Are there safety considerations worth raising with a clinician?

CoQ10 has generally been well tolerated in the published trials, with the 2007 meta-analysis noting an absence of significant side effects in the studies it pooled 5. Good tolerability under controlled conditions is not a blanket safety statement for every person and every situation.

The considerations worth raising are practical. Possible interaction with blood thinning medicines is a recognised reason for a pharmacist or prescriber to know about any supplement you take. Pregnancy, breastfeeding, active cancer care and upcoming surgery all change the calculation, and those decisions belong to the clinical team. Supplements are also regulated differently from medicines, so product quality and actual content vary between manufacturers in ways a label does not always reveal.

And there is an opportunity cost that rarely gets named. Time and attention spent on a supplement with a contested effect is time not spent on sleep, activity, alcohol, body composition and sodium, where the effect on blood pressure is far better established. Discuss any result or any planned change in therapy with a clinician or licensed provider who can see your whole record.

When is a blood pressure reading worth discussing promptly?

When readings are consistently elevated over several days of home measurement, when they rise sharply from your own baseline, or when they come with symptoms such as chest pain, breathlessness, visual change, severe headache or new neurological symptoms. Those situations are worth contacting a clinician about promptly rather than monitoring alone.

For everything else, the useful habit is measurement done properly. Sit quietly for a few minutes beforehand, keep your back supported and feet flat, rest your arm at heart level, use a validated cuff that fits, and take more than one reading. Record them over a week or two and bring the record, since a pattern tells a clinician far more than a single number taken after a stressful commute.

If you are looking at both a blood pressure log and a lab panel, the panel adds context that a cuff cannot. Kidney function, electrolytes, thyroid status and metabolic markers all shape blood pressure, and a clinician reading them together can distinguish a lifestyle pattern from something that needs a different kind of attention.

Key takeaways

For related reading on nutrients and blood pressure questions, see will vitamin b12 increase blood pressure.

References

  1. The protective effects of coenzyme Q10 on blood pressure: a narrative review of anti-inflammatory and antioxidant mechanisms. Inflammopharmacology, 2025.
  2. Coenzyme Q10 treatment of cardiovascular disorders of ageing including heart failure, hypertension and endothelial dysfunction. Clinica Chimica Acta, 2015.
  3. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. The Cochrane Database of Systematic Reviews, 2016.
  4. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. The Cochrane Database of Systematic Reviews, 2009.
  5. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension, 2007.
  6. Coenzyme Q10 as Adjunctive Therapy for Cardiovascular Disease and Hypertension: A Systematic Review. The Journal of Nutrition, 2022.
  7. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. European Journal of Clinical Nutrition, 2002.
  8. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. Southern Medical Journal, 2001.
  9. Role of coenzyme Q10 in chronic heart failure, angina, and hypertension. Pharmacotherapy, 2001.
  10. Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. BioFactors, 2003.
  11. Coenzyme Q10: a therapy for hypertension and statin-induced myalgia?. Cleveland Clinic Journal of Medicine, 2010.

Common questions

Does CoQ10 lower blood pressure in everyone who takes it?

No. Reported responses have varied widely, and the most recent Cochrane review concluded that no clinically significant effect on blood pressure could be confirmed. Earlier pooled analyses reported reductions, which is why sources disagree. Any real effect appears modest and inconsistent between individuals, so it should never be assumed in advance.

Why do some sources claim CoQ10 lowers systolic pressure by up to 17 mmHg?

That figure dates from 2007 and was described as a potential upper bound rather than an average result. Later and stricter reviews did not confirm effects of that size. Treat it as the most favourable possible reading, not as what a person should expect.

Can CoQ10 replace blood pressure medication?

No. CoQ10 is not established as a replacement for prescribed therapy. Blood pressure medicine is adjusted by the prescriber using your readings over time and your full clinical picture. A licensed provider evaluates whether any change is appropriate.

Does a low CoQ10 blood level mean supplementing will lower my blood pressure?

There is no established link between a baseline CoQ10 level and how a person's blood pressure responds to supplementation. A level tells you where you sit relative to the lab's range, which may reflect age, circulating lipids, certain medicines or assay variation. It is a conversation starter with a clinician, not a prediction.

How long did the blood pressure trials run?

Most have been short, running only weeks to a few months rather than years. That is one of the main limitations of what is known, since cardiovascular outcomes play out over much longer timescales. Short duration also means nothing is known about sustained effects over years.

Is CoQ10 considered safe?

It is generally regarded as well tolerated. That is not a blanket safety statement. Possible interaction with blood thinning medicines, pregnancy, active cancer care and upcoming surgery all warrant a conversation with a pharmacist or clinician first.

What moves blood pressure more reliably than a supplement?

Sodium intake, body composition, alcohol, aerobic activity, sleep quality and untreated sleep apnoea all have stronger and better replicated relationships with blood pressure than any single supplement. Those are also the factors a clinician will look at first, alongside kidney function, electrolytes, thyroid status and metabolic markers from a blood panel.

Related reading